Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. provided consolidated earnings guidance for the six months ended June 30, 2015. The company expects it is expected that the consolidated profit attributable to the equity holders of the Company for the six months ended June 30, 2015 may record a decrease by not more than 50% as compared with that for the corresponding period in 2014.

Such decrease that may be recorded was mainly due to a decrease in revenue of the manufacturing and selling of medicines segment which resulted from a drop in the sales volume of Compound Liquorice Tablets; a slow pace in the drug tender progress for the new product namely Tegafur, Gimeracil and Oteracil Potassium Tablets; and an increase in the Group's research and development input.